LeMaitre Sign on the Building
Play Video

Press Release

LeMaitre Q3 2021 Financial Results

October 28, 2021 at 4:05 PM EDT

BURLINGTON, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

Q3 2021 Financial Results

  • Sales of $38.4mm, +5% (+5% organic) vs. Q3 2020
  • Gross margin of 64.8%, +250 basis points
  • Op. income of $9.1mm, -9%
  • Op. margin of 24%
  • Net income of $6.5mm, -13%
  • Earnings of $0.30 per diluted share, -19%
  • EBITDA of $11.3mm, -10%

Q3 2021 sales were driven by Artegraft, allografts and valvulotomes. The Americas and EMEA both grew 5%, while APAC was up 16%. Due to the Delta variant, many hospitals deferred elective surgeries.

The 250 basis point gross margin improvement was due to year-ago Artegraft purchase price accounting, which reduced the Q3 2020 gross margin. This was somewhat offset by Q3 2021 manufacturing inefficiencies.

Q3 2021 op. income of $9.1mm was down 9% as op. expenses increased 24%. This increase was due to a 14% headcount increase, as well as additional selling and marketing expenses. As of October 28, 2021 the Company employed 103 sales representatives.

Cash and investments increased to $67.1mm on September 30, 2021 due to the recent stock offering (net proceeds of $58.7mm) and Q3 EBITDA of $11.3mm. In July, the Company also paid off the remaining Artegraft acquisition debt.

George LeMaitre, Chairman and CEO, said, “Although the Delta variant impacted Q3 sales, we delivered a 24% op. margin while rebuilding headcount and the salesforce back to pre-COVID levels.”

Business Outlook

Item Q4 2021 Guidance Full Year 2021 Guidance
Sales $39.0mm - $41.0mm
(Midpoint: $40.0, +7%)
$153.9mm - $155.9mm
(Midpoint: $154.9, +20%)
Gross Margin 66.3% 65.8%
Op. Income $8.3mm - $9.7mm
(Midpoint: $9.0mm, -6%)
$36.5mm - $37.8mm
(Midpoint: $37.1mm, +29%)
EPS $0.29 - $0.34
(Midpoint: $0.31, -8%)
$1.26 - $1.31
(Midpoint: $1.29, +24%)

Quarterly Dividend

On October 26, 2021, the Company's Board of Directors approved a quarterly dividend of $0.11/share of common stock. The dividend will be paid on December 2, 2021 to shareholders of record on November 19, 2021.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 844-239-5284 (+1 512-961-6497 for international callers), using passcode 8308248. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit http://www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre Vascular management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with foreign regulatory requirements to market and sell our products outside the United States; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

             
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)          
CONDENSED CONSOLIDATED BALANCE SHEETS        
(amounts in thousands)          
             
             
      September 30, 2021   December 31, 2020  
      (unaudited)      
Assets          
             
Current assets:          
  Cash and cash equivalents   $ 17,369     $ 26,764    
  Short-term marketable securities     49,710       214    
  Accounts receivable, net     19,501       19,552    
  Inventory and other deferred costs     44,326       45,115    
  Prepaid expenses and other current assets     3,110       2,618    
Total current assets     134,016       94,263    
             
Property and equipment, net     16,997       15,036    
Right-of-use leased assets     15,664       16,066    
Goodwill     65,945       65,945    
Other intangibles, net     54,230       58,905    
Deferred tax assets     1,627       1,686    
Other assets     994       909    
             
Total assets   $ 289,473     $ 252,810    
             
             
Liabilities and stockholders' equity          
             
Current liabilities:          
  Current portion of long-term debt   $ -     $ 2,500    
  Accounts payable     3,137       2,394    
  Accrued expenses     16,460       17,525    
  Acquisition-related obligations     616       772    
  Lease liabilities - short-term     1,901       1,954    
Total current liabilities     22,114       25,145    
             
Long-term debt     -       35,532    
Lease liabilities - long-term     14,589       14,791    
Deferred tax liabilities     122       127    
Other long-term liabilities     3,600       4,643    
Total liabilities     40,425       80,238    
             
Stockholders' equity          
  Common stock     234       221    
  Additional paid-in capital     179,070       114,924    
  Retained earnings     84,356       70,554    
  Accumulated other comprehensive loss     (2,636 )     (1,525 )  
  Treasury stock     (11,976 )     (11,602 )  
Total stockholders' equity     249,048       172,572    
             
Total liabilities and stockholders' equity   $ 289,473     $ 252,810    
             


LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)            
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS        
(amounts in thousands, except per share amounts)              
(unaudited)              
                 
    For the three months ended   For the nine months ended
    September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020
                 
Net sales $ 38,368     $ 36,416     $ 114,921     $ 91,818  
Cost of sales   13,502       13,712       39,495       31,602  
                 
Gross profit   24,866       22,704       75,426       60,216  
                 
Operating expenses:              
  Sales and marketing   6,941       5,157       20,210       17,788  
  General and administrative   6,004       5,901       18,748       16,425  
  Research and development   2,848       2,098       8,344       7,230  
  Gain on sale of building   -       (470 )     -       (470 )
Total operating expenses   15,793       12,686       47,302       40,973  
                 
Income from operations   9,073       10,018       28,124       19,243  
                 
Other income (expense), net              
  Interest income   54       15       56       194  
  Interest expense   (621 )     (665 )     (1,693 )     (732 )
  Foreign currency gain (loss)   (72 )     10       (105 )     (280 )
                 
Income before income taxes   8,434       9,378       26,382       18,425  
                 
Provision for income taxes   1,930       1,865       5,650       4,238  
                 
Net income $ 6,504     $ 7,513     $ 20,732     $ 14,187  
                 
Earnings per share of common stock              
  Basic $ 0.30     $ 0.37     $ 0.99     $ 0.70  
  Diluted $ 0.30     $ 0.37     $ 0.98     $ 0.69  
                 
Weighted - average shares outstanding:              
  Basic   21,592       20,254       20,920       20,201  
  Diluted   21,935       20,474       21,251       20,434  
                 
                 
Cash dividends declared per common share  $ 0.110     $ 0.095     $ 0.330     $ 0.285  
                 


                                 
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)                        
SELECTED NET SALES INFORMATION                            
(amounts in thousands)                              
(unaudited)                              
                                 
                                 
    For the three months ended   For the nine months ended
    September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020
    $   %   $   %   $   %   $   %
Net Sales by Geography                              
  Americas $ 25,299   66 %   $ 24,184   66 %   $ 76,327   67 %   $ 57,462   63 %
  Europe/Middle East/Africa   10,535   27 %     10,039   28 %     31,200   27 %     28,339   31 %
  Asia/Pacific Rim   2,534   7 %     2,193   6 %     7,394   6 %     6,017   6 %
Total Net Sales $ 38,368   100 %   $ 36,416   100 %   $ 114,921   100 %   $ 91,818   100 %
                                 


                       
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)                  
NON-GAAP FINANCIAL MEASURES                  
(amounts in thousands)                  
(unaudited)                  
                       
Reconciliation between GAAP and Non-GAAP sales growth:                  
  For the three months ended September 30, 2021                  
    Net sales as reported   $ 38,368                
    Impact of currency exchange rate fluctuations     (231 )              
        Adjusted net sales       $ 38,137            
                       
  For the three months ended September 30, 2020                  
    Net sales as reported   $ 36,416                
        Adjusted net sales       $ 36,416            
                       
    Adjusted net sales increase for the three months ended September 30, 2021   $ 1,721       5 %      
                       
                       
                       
        For the three months ended   For the nine months ended  
        September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020  
Reconciliation between GAAP and Non-GAAP EBITDA                  
  Net income as reported   $ 6,504     $ 7,513     $ 20,732     $ 14,187    
  Interest (income) expense, net     567       650       1,637       538    
  Amortization and depreciation expense     2,340       2,599       7,117       5,778    
  Provision for income taxes     1,930       1,865       5,650       4,238    
                       
  EBITDA   $ 11,341     $ 12,627     $ 35,136     $ 24,741    
                       
  EBITDA percentage increase (decrease)         -10 %         42 %  
                       

CONTACT: 
J.J. Pellegrino, CFO, LeMaitre
781-425-1691
jjpellegrino@lemaitre.com

Primary Logo

Source: LeMaitre Vascular, Inc.